John F. Seymour
Peter MacCallum Cancer Centre
781 Papers
5.1K Citations
John F. Seymour is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 96, co-authored 706 publications. Previous affiliations of John F. Seymour include Royal Children's Hospital & St. Vincent's Health System.
Chat about Author
Papers
Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
Rami S. Komrokji,Martha Wadleigh,John F. Seymour,Andrew W. Roberts,Luen Bik To,Huan J. Zhu,Ruben A. Mesa +6 more
TL;DR: Pacritinib shows promising efficacy in alleviating MF-associated splenomegaly and constitutional symptoms at a dose that induces minimal myelosuppression, and is chosen as the recommended dose (RD) for Phase 2 study.
83
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
TL;DR: Preliminary observations suggest fludarabine-based non-myeloablative chemotherapy followed by reinfusion of G-CSF-mobilised allogeneic peripheral blood progenitor cells results in engraftment and GVHD/graft-versus-tumour effects similar to myeloablatives and may provide an alternative in patients ineligible for conventional conditioning regimens.
75
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
Arjan A. van de Loosdrecht,Robin M. Ireland,Wolfgang Kern,Matteo G. Della Porta,Canan Alhan,Jan Sebastian Balleisen,Peter Bettelheim,David T. Bowen,Kate Burbury,Lisa Eidenschink,Mario Cazzola,Spencer S. C. Chu,Matthew J. Cullen,Jevon Cutler,Angelika M. Dräger,Jean Feuillard,Pierre Fenaux,Patricia Font,Ulrich Germing,Detlef Haase,Eva Hellström-Lindberg,Ulrika Johansson,Shahram Kordasti,Michael R. Loken,Luca Malcovati,Jeroen G. te Marvelde,Sergio Matarraz,T. Milne,B. Moshaver,Ghulam J. Mufti,Veselka Nikolova,Kiyoyuki Ogata,Uta Oelschlaegel,Alberto Orfao,Gert J. Ossenkoppele,Anna Porwit,Uwe Platzbecker,Frank Preijers,Katherina Psarra,Stephen J. Richards,Dolores Subirá,John F. Seymour,Vicky Tindell,Teresa Vallespi,Peter Valent,Vincent H.J. van der Velden,Denise A. Wells,Theo de Witte,Florian Zettl,Marie C. Béné,Theresia M. Westers +50 more
TL;DR: The rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.
70
Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older.
Linda Mileshkin,John F. Seymour,Max Wolf,P. Gates,E. H. Januszewicz,P. Joyce,Henry Miles Prince +6 more
TL;DR: Patients aged ⩾60 years are more susceptible to cardiovascular toxicities, particularly atrial fibrillation, but have similar or better response rates following HDT and similar long-term outcomes to younger patients.
69
The landscape of new drugs in lymphoma
Anas Younes,Stephen M. Ansell,Nathan Fowler,Wyndham H. Wilson,Sven de Vos,John F. Seymour,Ranjana H. Advani,Andres Forero,Franck Morschhauser,Marie José Kersten,Kensei Tobinai,Pier Luigi Zinzani,Emanuele Zucca,Jeremy S. Abramson,Julie M. Vose +14 more
TL;DR: The most-promising agents in clinical development for the treatment of lymphoma are described, and expert opinion on new strategies that might enable more streamlined drug development is provided.
69